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Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an 
increased risk of fractures. Reduced blood supply and bone strength may contribute to 
this skeletal fragility. We hypothesized that long-term administration of Exenatide, a glu-
cagon-like peptide-1 receptor agonist, would improve bone architecture and strength of 
T2DM mice by increasing blood flow to bone, thereby stimulating bone formation. In this 
study, we used a model of obesity and severe T2DM, the leptin receptor-deficient db/db 
mouse to assess alterations in bone quality and hindlimb blood flow and to examine 
the beneficial effects of 4 weeks administration of Exenatide. As expected, diabetic mice 
showed marked alterations in bone structure, remodeling and strength, and basal vascu-
lar tone compared with lean mice. Exenatide treatment improved trabecular bone mass 
and architecture by increasing bone formation rate, but only in diabetic mice. Although 
there was no effect on hindlimb perfusion at the end of this treatment, Exenatide admin-
istration acutely increased tibial blood flow. While Exenatide treatment did not restore the 
impaired bone strength, intrinsic properties of the matrix, such as collagen maturity, were 
improved. The effects of Exenatide on in vitro bone formation were further investigated 
in primary osteoblasts cultured under high-glucose conditions, showing that Exenatide 
reversed the impairment in bone formation induced by glucose. In conclusion, Exenatide 
improves trabecular bone mass by increasing bone formation and could protect against 
the development of skeletal complications associated with T2DM.
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inTrODUcTiOn
Bone fragility is an important complication in patients with type 2 diabetes mellitus (T2DM), despite 
a normal or high-bone mineral density (BMD) (1), implying alterations of bone quality (2). The 
cellular and molecular mechanisms leading to the reduced bone strength and quality in T2DM 
patients are poorly characterized; but accumulation of advanced glycation end products, as a result 
of hyperglycemia and oxidative stress, changes in collagen cross-linking and suppression of bone 
turnover are thought to be significant contributors in the etiology of diabetic fractures (3, 4).
Glycemic control has been evidenced as a major intervention to reduce fracture in T2DM (5), 
suggesting that early lifestyle intervention and administration of anti-diabetic medications to reduce 
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hyperglycemia are required. However, the choice of anti-diabetic 
medications is crucial as some anti-diabetic therapies can them-
selves result in increase in fracture risk by augmenting the risk 
of hypoglycemia and falls or by altering bone turnover and bone 
quality.
Incretin hormones, such as glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic peptide (GIP), are pep-
tides secreted in the gastrointestinal tract that stimulate insulin 
secretion in response to the ingestion of nutrients in a glucose-
dependent manner and as such avoidance of hypoglycemia events 
(6). In opposition to GIP, GLP-1 resistance does not seem to occur 
in T2DM and as a result, GLP-1 receptor agonists (GLP-1RAs), 
including Exenatide, have been developed and marketed for the 
treatment of T2DM (6). A growing body of evidence suggest 
positive effects of GLP-1 or GLP-1RAs on bone physiology as 
demonstrated by rapid changes in gene expression or bone mass 
in several rodent models of ovariectomy-induced osteoporosis, 
genetically inherited or high-fat diet-induced T2DM (7–11). 
However, the possible effects of GLP-1RAs on bone quality that 
is compromised in T2DM, is still lacking. Based on evidences that 
Glp1r KO mice and GLP-1RA-treated osteoporotic mice, exhibit 
modifications of bone quality (12–14), we hypothesized that 
GLP-1RAs could improve bone quality in T2DM.
Furthermore, bone perfusion strongly correlates with meta-
bolic activity and bone formation (15). This is dependent upon 
the number and size of blood vessels, which are regulated through 
the processes of angiogenesis and vasomotor function, respec-
tively. Sufficient blood supply is crucial for bone formation, bone 
turnover, and fracture healing, poor blood supply being a major 
cause of impaired bone formation and delayed bone healing in 
the elderly and in osteoporosis (16, 17). T2DM is often associated 
with impaired vascular function (18) and a high risk of vascular 
disorders (19). Interestingly, it has been shown that administra-
tion of GLP-1RAs to T2DM patients attenuates hypertension, 
increases renal blood flow, and improves vascular endothelial 
function (20). Moreover, GLP-1R is expressed in endothelial and 
vascular smooth muscle cells (21), suggesting that GLP-1RAs may 
increase blood flow to bone, thereby stimulating bone formation.
The diabetic db/db mouse is a widely used model of severe 
T2DM because of its shared features with human diabetes (22). 
These mice possess a mutation in the adipokine leptin receptor 
gene that causes obesity and subsequent spontaneous develop-
ment of T2DM-like pathology, including early hyperlipidemia 
and hyperinsulinemia, followed by persistent hyperglycemia 
and decreased insulin secretion, as a result of pancreatic β-cell 
dysfunction (23). db/db mice exhibit skeletal fragility compared 
with their lean controls (22), in particular impaired trabecular 
and cortical microarchitectures and reduced bone strength due to 
poor bone quality (22, 24, 25). Interestingly, an analog of the sister 
incretin hormone GIP has been shown to significantly improve 
bone quality and hence bone strength in the db/db mice (25). In 
the shed of these results, it is clinically important to assess the 
effects of marketed GLP-1RAs on bone strength and quality in 
this rodent model.
The aims of the present study were to ascertain whether 
Exenatide can improve bone quality and strength in diabetic mice 
by studying bone microarchitectures, tissue material properties, 
cellular activities, and hindlimb blood flow in  vivo. We also 
compared the effects of Exenatide on in vitro bone formation by 
osteoblasts cultured in low- and high-glucose environments.
MaTerials anD MeThODs
animals and study Design
Twenty male diabetic (db/db) mice (BKS.Cg-+Leprdb/+Leprdb/
OlaHsd) and 20 male lean mice (BKS.Cg-Dock7m+/+Leprdb/
OlaHsd) were purchased from Harlan Laboratories (Shardlow, 
UK) at 6 weeks of age and acclimatized to their housing (21 ± 1°C; 
12 h day/night cycle) for 1 week. They were weighed and blood 
glucose measured at the end of each week using a glucometer 
(Accu-chek Aviva, Roche Diagnostics, UK). All mice were dia-
betic [blood glucose > 12 mmol/L (26)] at 9 weeks of age. Then, 
both lean and db/db mice were randomly allocated to treatment 
with saline (saline control and diabetic control) or 10 μg/kg/day 
Exenatide (Bachem, Switzerland) (n =  10/group). Sample size 
calculations were based on previous work comparing Exenatide’s 
effect to saline and db/db mice to lean mice on the most relevant 
parameter for bone mass, the bone volume percentage (BV/TV) 
(14, 25) to achieve 80% power of detecting the difference with 5% 
of type 1 error rate.
Treatments were administered by daily subcutaneous injec-
tions for 4 weeks. At days 8 and 3 prior to euthanasia, mice were 
intraperitoneally injected with calcein (20  mg/kg) and alizarin 
red complexone (30 mg/kg) (Sigma, UK), respectively, to label 
bone-mineralizing surfaces. After necropsy, tibias and femurs 
were collected and cleaned of soft tissues. All animal procedures 
were approved by the institutional Ethics and Welfare committee 
and were carried out under UK Home Office license to comply 
with the Animals (Scientific Procedures) Act 1986 (PPL: 70/7859).
Measurements of Whole hindlimb Bone 
Perfusion in db/db Mice
Two days before blood flow measurement, the hair of the right 
hindlimb of db/db mice was removed with a depilatory cream. 
Perfusion was measured in the right hindlimb using laser Doppler 
imaging (LDI) (MoorLDI2 Imager, Moor Instruments Ltd., UK). 
The animals were placed in the supine position during LDI meas-
urement and the mean perfusion was estimated from the thigh to 
the foot to cover the tibia artery and vein. The distance between 
the camera and the hindlimb skin surface was 20 cm.
To analyze the acute effects of Exenatide on hindlimb perfu-
sion, mice were anesthetized using isofluorane, recordings were 
started 8  min before a subcutaneous injection of Exenatide 
(baseline) and continued during the following 30  min. LDI 
measures the distribution of blood flux (combination of veloc-
ity and concentration of red blood cells) in arbitrary units for 
a selected region of interest (19  mm ×  27  mm) with a spatial 
resolution of 100μm/pixel. The estimated maximum depth of 
detectable vessels (in soft connective tissues) was 2–3 mm (laser 
wavelength  =  830  nm). LDI generates color-coded perfusion 
maps of larger tissue areas which allow the recording of precisely 
delimited regions of interest compatible for specific long bone 
perfusion measurements in mice (27).
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Micro-cT analysis of Tibiae
Right tibiae were fixed in 4% formaldehyde for 48 h and stored in 
70% ethanol at 4°C. To analyze bone microarchitecture, trabecular 
and cortical compartments were scanned using high-resolution 
micro-computed tomography (Skyscan-1172/F Bruker, Belgium) 
operated at 55 kV, 180 µA, 1,710 ms integration time. The isotropic 
voxel size was fixed at 5 µm, the rotation step at 0.6°, and exposure 
was performed using a 0.5 mm aluminum filter. After scanning, 
whole tibiae were reconstructed using NRecon version 1.6.9.8 
(Skyscan), trabecular and cortical bone areas were analyzed with 
CT-Analyser version 1.14.4.1 (Skyscan), and the quantification 
of bone structure was made using the analysis software Batman 
v.1.14.4.1. Trabecular parameters were assessed in the proximal 
metaphysis; 0.5 mm below the growth plate was left unanalyzed 
and the 2 mm following down was analyzed. These included: BV/
TV, trabecular thickness (Tb.Th), trabecular number (Tb.N), 
structure model index (SMI), trabecular bone pattern factor (Tb.
Pf), and trabecular separation (Tb.Sp). Analysis of cortical bone 
in the midshaft diaphysis was performed using a 0.5  mm long 
segment at 50% of the total tibia length. Parameters consisted of: 
tissue area (Tt.Ar), tissue perimeter (Tt.Pm), bone area (Ct.Ar), 
eccentricity (Ecc), maximum bending rigidity (Imax), and cross-
sectional thickness (Ct.Th). The threshold values for the micro-
CT analysis of trabecular bone were chosen to be between 60 and 
255 and between 100 and 255 for cortical bone. All parameters 
were measured according to guidelines and nomenclature pro-
posed by the American Society for Bone and Mineral Research 
(ASBMR) (28).
Bone histomorphometry
Following micro-CT, tibiae of db/db and lean mice were dehy-
drated in acetone for 24 h and embedded in methylmethacrylate 
(MMA, Sigma, UK) at low temperature. Unstained 8-μm thick 
longitudinal sections were used for fluorescence microscopy to 
visualize mineralizing surfaces. The extent of the mineralizing 
surfaces was expressed as the alizarin red-labeled surfaces per 
unit bone surface (MS/BS). Mineral apposition rate (MAR) 
and bone formation rate (BFR) were calculated as previously 
described (14). Alternatively, sections were stained for tartrate-
resistant acid phosphatase (TRAP) (Leucognost® SP; Merck, 
Germany) and counterstained with Mayer’s hematoxylin solu-
tion to visualize osteoclasts on trabecular bone, or subjected to 
Goldner’s staining to quantify trabecular bone microarchitecture 
parameters. Parameters were measured in the trabecular bone of 
the metaphysis, using a 1 mm region of interest below the growth 
plate. Measurements were performed using image analysis soft-
ware (Explora Nova, La Rochelle, France) and parameters were 
reported in accordance with the ASBMR nomenclature (29).
Mechanical Testing
Whole bone strength was assessed by three-point bending 
performed on the left femurs of db/db and lean mice. Prior to 
mechanical testing, the femurs were hydrated in saline for 24 h 
at room temperature. Measurements were performed with a con-
stant span length of 10 mm on an Instron 5942 (Instron, France). 
Femurs were positioned horizontally, with the anterior surface 
facing upward, centered on the support, and the pressing force 
was applied vertically to the bone midshaft. Each bone was tested 
with a loading speed of 2 mm/min until failure with a 500 N load 
cell, as reported previously (13). The load-displacement curve 
was acquired using Bluehill 3 software (Instron) and ultimate 
load, ultimate displacement, stiffness, and work to fracture were 
quantified.
evaluation of Bone Mineral Density 
Distribution (BMDD)
Quantitative backscattered electron imaging (qBEI) was employed 
to determine the BMDD in the MMA-embedded blocks above, 
as previously described (30). MMA blocks were carbon-coated 
and observed with a scanning electron microscope (EVO LS10, 
Carl Zeiss Ltd., Nanterre, France) equipped with a five-quadrant 
semi-conductor backscattered electron detector and operated at 
20 keV, with a probe current of 250 pA and a working distance of 
15 mm. The backscattered signal was calibrated as described (25). 
Four images per sample of cortical bone, centered 4 mm below 
the growth plate, were imaged at a 200× nominal magnification, 
corresponding to a pixel size of 0.5 µm. Analyses were performed 
to obtain variables from the BMDD: Camean, representing the aver-
age calcium concentration, Capeak, the most frequently occurring 
calcium concentration, and Cawidth, the width of the histogram at 
the half maximum level.
Fourier-Transform infrared Microscopy 
(FTirM) at sites of Bone Formation
The same MMA-embedded blocks used for histomorphometry 
were utilized for FTIRM. Longitudinal tibia sections (4-µm thick-
ness) were sandwiched between BaF2 optical windows. Spectral 
analysis was obtained on a Bruker Vertex 70 spectrometer (Bruker 
Optics, Germany) interfaced with a Bruker Hyperion 3000 infra-
red microscope. For FTIRM analysis at site of bone formation, 
12 spectra on each bone were acquired between the alizarin red 
and calcein labeling and analyzed with Opus Software (release 
6.5, Bruker). The contribution of the embedding MMA and water 
vapor were corrected prior to baseline correction. Individual 
spectra were then subjected to curve fitting after obtaining a sec-
ond derivative, using a commercially available software package 
(Grams/AI 8.0, Thermofisher Scientific, France). The parameters 
(25) were: (a) mineral-to-matrix ratio; (b) mineral maturity; (c) 
the carbonate-to-phosphate ratio; and (d) the collagen maturity 
index. All relevant calculations were described in Ref. (31).
In Vitro Bone Formation by Primary 
Osteoblasts
Primary mouse osteoblastic cells were obtained by sequential 
enzyme digestion of excised calvarial bones from 2-day-old 
C57BL/6 mice using a three-step process (32). Cells were 
cultured in minimum essential media (MEM) for 2–3  days at 
37°C in 5% CO2 until they reached confluence. They were then 
cultured in six-well trays in MEM supplemented with 2  mM 
β-glycerophosphate and 50  µg/mL ascorbic acid, containing 
either normal (5.5 mM) or high- (22 mM) glucose concentrations, 
using mannitol (22 mM) as an osmotic control. Exenatide (0, 25, 
FigUre 1 | Body mass and blood glucose in db/db and control mice. Body mass and blood glucose levels were measured weekly in db/db and lean mice. 
Injections of Exenatide started at week 9 and continued daily for 4 weeks. (a) Body mass in relation to age in lean, diabetic, and Exenatide-treated mice from 7 to 
13 weeks of age. (B) Blood glucose levels in lean, diabetic, and Exenatide-treated mice from 7 to 13 weeks of age. Bars represent mean ± SD for n = 10 mice/
group, ****P < 0.0001 saline-treated diabetic versus saline-treated lean; #P < 0.05; ####P < 0.0001 Exenatide-treated diabetic versus saline-treated diabetic mice.
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50, and 100 nM) was added to the culture (one plate/treatment). 
Bone nodule formation by osteoblasts was measured after 28 days 
of culture. Experiments were terminated by fixing cell layers in 
4% paraformaldehyde for 10 min; mineralized bone nodules were 
visualized and quantified unstained. Bone nodules were scanned 
at 800 dpi using a high-resolution flat-bed scanner. Binary images 
of each individual well were then subjected to automated analysis 
(Image J), using constant “threshold” and “minimum particle” 
levels, to determine the number and surface area of mineralized 
bone nodules, as previously described (32).
statistics
Data are presented as mean ±  SD except for acute blood flow 
where they are presented as mean ± SEM to facilitate visibility. 
Multiple comparisons were performed using two-way analysis 
of variance and Tukey’s multiple comparison post hoc test where 
appropriate. P < 0.05 was considered to be statistically significant.
resUlTs
effect of exenatide on Body Mass, Obesity 
status, and Blood glucose in db/db Mice
The development of diabetes in db/db mice was identified by 
measuring body mass and blood glucose. The body mass of 
db/db mice was significantly higher than that of lean mice at 
all time-points, consistent with severe obesity. Administration 
of Exenatide treatment for 4  weeks slightly reduced this in 
db/db mice (by 6–7%) compared with saline-treated db/db 
mice (P < 0.01) despite the mice still being obese (Figure 1A). 
Exenatide had no effect in lean mice (Figure 1A).
Saline-treated db/db mice exhibited dramatically higher blood 
glucose than saline-treated lean mice at 7–8 weeks [by 2.1-fold 
(P  <  0.001)] and at 12–13  weeks [by 3.5-fold (P  <  0.0001)] 
(Figure 1B). The mice were all diabetic by 9 weeks of age. These 
data confirm significant impairment of glycemic control in these 
mice. Injection of Exenatide into db/db mice decreased the blood 
glucose levels in the first week of treatment by 31% (P < 0.0001) 
and in the last week by 42% (P < 0.0001) compared with saline-
treated db/db mice. However, Exenatide had no effect on blood 
glucose in lean mice.
chronic and acute effects of exenatide  
on hindlimb Blood Flow in db/db Mice
Acute changes induced by Exenatide in hindlimb perfusion were 
measured by LDI in all mice. After 15 min injection, Exenatide 
significantly stimulated blood perfusion in tibiae of db/db mice 
compared with the saline-treated ones. This vasodilatory effect 
of Exenatide increased over time for the 30  min following the 
injection, reaching a maximum 25% (P < 0.0001) greater than 
that in saline-treated db/db mice (Figures 2A,C). This increase 
in perfusion was also found in Exenatide-treated lean mice 
(P < 0.05) (Figure 2D).
Hindlimb perfusion was 44% lower in db/db mice (P < 0.0001) 
than in lean mice (Figures 2B,E) confirming that diabetic mice 
have impaired blood flow. The chronic effect of Exenatide on 
hindlimb perfusion after 4-week treatment was also assessed 
and our data show no differences in hindlimb perfusion between 
Exenatide-treated db/db and Exenatide-treated lean mice 
(Figure 2E). These data indicate that acute but not chronic treat-
ment with Exenatide increases hindlimb perfusion in db/db and 
lean mice.
effect of exenatide on Trabecular  
and cortical Bone Microarchitecture  
in db/db Mice
We assessed the possible effects of Exenatide on trabecular and 
cortical bone microarchitecture. As expected, saline-treated 
db/db mice exhibited lower trabecular bone mass and impaired 
micro-architectural parameters of connectivity and structure 
when compared with lean mice (Table 1). This low bone mass in 
db/db mice was significantly improved by Exenatide treatment, 
as shown by an increase in BV/TV (+49%, P < 0.01) compared 
with saline-treated db/db mice. This increase was associated 
with significant modifications of trabecular microarchitecture as 
FigUre 2 | Acute and chronic effects of Exenatide on hindlimb blood flow in db/db mice and control mice. (a,B) Representative images of mouse hindlimb 
perfusion, obtained by laser Doppler imaging (LDI). (a) Blood flow imaging of db/db mice with saline injection versus Exenatide. Images were acquired after a 25 min 
infusion of saline or Exenatide (10 μg/kg/day), (B) blood flow imaging of untreated lean mice versus db/db mice. Images were acquired after the 4 weeks of 
treatment. The colors in the heat maps indicate the maximum (red) and the minimum (blue) levels of perfusion, expressed in arbitrary units, representing the total 
blood flux (combination of velocity and concentration of red blood cells). (c,D) Time course graph of the average hindlimb perfusion monitored by LDI after 
Exenatide injection in db/db (c) and lean (D) mice. Exenatide (10 µg/kg) and saline were injected to mice after 8 min of baseline recording. Values are presented as 
mean ± SEM of n = 10 mice/group, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 versus saline. (e) Differences in hindlimb blood flow measured by LDI 
between the groups after 4-week treatment with Exenatide. Bars represent mean ± SD of n = 10 mice/group, ****P < 0.0001 versus lean mice.
TaBle 1 | Measurements of trabecular and cortical bone architecture in 
13-week-old db/db and lean mice treated with either Ex-4 or saline.
Parameters lean saline lean ex-4 db/db saline db/db ex-4
Trabecular architecture using micro-cT
BV/TV (%) 7.21 ± 1.37 7.83 ± 1.29 3.35 ± 0.51**** 5.00 ± 0.78##
Tb.Th (μm) 57.4 ± 2.9 58.1 ± 3.3 45.3 ± 2.2**** 49.1 ± 1.8##
Tb.N (/mm) 1.23 ± 0.24 1.36 ± 0.21 0.74 ± 0.12**** 1.02 ± 0.18##
Tb.Pf (/mm) 17.00 ± 4.78 15.25 ± 2.72 28.89 ± 2.10**** 20.62 ± 2.94####
SMI 1.9 ± 0.21 1.78 ± 0.15 2.18 ± 0.09**** 1.93 ± 0.13##
Tb.Sp (mm) 0.46 ± 0.03 0.45 ± 0.04 0.49 ± 0.03 0.46 ± 0.04
Trabecular architecture using histomorphometry
BV/TV (%) 11.25 ± 3.01 12.86 ± 3.06 4.53 ± 1.30**** 7.70 ± 1.21#
Tb.Th (μm) 39.5 ± 7.2 39.5 ± 4.3 26.3 ± 3.8**** 34.4 ± 4.0##
Tb.N (/mm) 3.47 ± 0.39 3.68 ± 0.46 1.68 ± 0.35**** 2.31 ± 0.37##
Tb.Sp (mm) 0.27 ± 0.05 0.25 ± 0.05 0.59 ± 0.10**** 0.44 ± 0.10##
cortical architecture using micro-cT
Tt.Ar (mm2) 1.00 ± 0.09 0.97 ± 0.08 0.85 ± 0.08** 0.80 ± 0.09
Tt.Pm (mm) 3.99 ± 0.19 3.93 ± 0.15 3.64 ± 0.18** 3.54 ± 0.18
Ct.Ar (mm2) 0.57 ± 0.06 0.55 ± 0.08 0.43 ± 0.06*** 0.40 ± 0.07
Ecc 0.55 ± 0.06 0.54 ± 0.07 0.46 ± 0.04* 0.45 ± 0.09
Imax (mm4) 0.14 ± 0.03 0.13 ± 0.03 0.09 ± 0.02*** 0.08 ± 0.02
Ct.Th (mm) 0.17 ± 0.01 0.17 ± 0.02 0.14 ± 0.02*** 0.13 ± 0.02
Measurements of trabecular architecture were performed in the proximal tibial 
metaphysis of db/db and lean mice using micro-CT or histomorphometry. 
Measurements of cortical architecture were made using micro-CT in the tibial midshaft 
diaphysis of db/db and lean mice.
BV/TV, bone volume percent; Tb.N, trabecular number; Tb.Pf, trabecular pattern factor; 
Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; SMI, structure model index; 
Tt.Ar, tissue area; Tt.Pm, tissue perimeter; Ct.Ar, bone area; Ecc, eccentricity; Imax, 
maximal moment of inertia; Ct.Th, cross-sectional thickness.
Mean ± SD of n = 10 mice/group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
versus lean saline. #P < 0.05, ##P < 0.01, ####P < 0.0001 versus db/db saline.
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evidenced by higher values for Tb.N (+38%, P < 0.01) and Tb.Th 
(+8%, P <  0.01) and lower values for microarchitecture, Tb.Pf 
(−29%; P < 0.0001) and SMI (−12%; P < 0.01) (Table 1). These 
beneficial effects of Exenatide in diabetic mice were confirmed 
by bone histomorphometry performed on 2D sections (Table 1). 
Tb.Sp was improved by Ex-4 with histomorphometry but not 
by micro-CT. One reason for this difference can be that meas-
urements made by histomorphometry are performed in 2D, in 
contrast to micro-CT where there are performed in 3D, and are 
therefore less accurate. Indeed, in 3D, Tb.Sp is calculated inde-
pendently of Tb.N and Tb.Th and it has been previously shown 
that derived Tb.Sp using 2D sections can be different from when 
measured directly in 3D and may yield in biased results (33).
Consistent with the trabecular bone changes, cortical bone 
geometry was also impaired in db/db mice (Table 1). However, our 
results revealed no differences in any cortical parameter following 
Exenatide treatment of both lean and db/db mice (Table 1).
effect of exenatide on In Situ Bone 
Turnover in db/db Mice
We next examined whether amelioration of trabecular micro-
architecture in Exenatide-treated db/db mice was due to a change 
in osteoblast activity or osteoclast numbers. As expected, BFR/
BS was lower in db/db mice than in lean mice. Exenatide treat-
ment increased this parameter by 44.5% in db/db mice (P < 0.01) 
compared with saline-treated ones. This augmentation in BFR/
BS was due to higher MAR (+28%; P < 0.01) (Figures 3A–C). 
On the other hand, Exenatide treatment had no effect in lean 
FigUre 3 | Effect of Exenatide on bone turnover parameters in db/db and control mice. Measurements were performed by bone histomorphometry on the 
trabecular region of tibial sections from 13-week-old db/db and lean mice treated with either Exenatide (10 μg/kg/day) or saline. (a) Bone formation rate (BFR).  
(B) Mineral apposition rate (MAR). (c) Mineralizing surfaces MS/BS. (D) Tartrate-resistant acid phosphatase (TRAP)-positive osteoclastic surfaces per millimeter  
of trabecular bone surface. Bars represent mean ± SD of n = 10 mice/group, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus lean Sal; ##P < 0.01, ###P < 0.001 
versus diabetic Sal.
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mice. We did not observe any significant differences in the 
number of TRAP-positive osteoclastic surfaces among the groups 
(Figure 3D), suggesting that bone resorption was not affected by 
diabetes or Exenatide treatment in lean and diabetic animals.
effect of exenatide on In Vitro Bone 
Formation in high-glucose conditions
In order to assess whether the above effects were due to direct 
action of exenatide on bone cells, we investigated the effect of 
Exenatide on bone formation by primary osteoblasts under 
high-glucose conditions. Similar to our previous findings (14), 
we found no effect of Exenatide on bone formation in  vitro 
when osteoblasts were cultured in normal glucose concentra-
tions. In contrast, a sevenfold reduction (P <  0.0001) in bone 
nodule formation was observed under high-glucose conditions 
(Figure 4A). The area of bone nodule formation in the presence 
of mannitol was similar to that generated in normal glucose 
conditions, suggesting that the inhibition of bone formation 
observed in high-glucose medium was not induced by extracel-
lular hyperosmolarity. Exenatide treatment increased the area of 
bone nodule formation by osteoblasts cultured in high-glucose 
medium by twofold (P < 0.001) and threefold (P < 0.0001) with 
concentrations of 50 and 100 nM, respectively, while it had no 
effect when osteoblasts were cultured in low-glucose concentra-
tions (Figure 4B).
effect of exenatide on Bone Mechanical 
strength in db/db Mice
Figure 5A represents an example of load/deformation curves that 
were recorded in the four groups. As expected, db/db mice had 
compromised bone strength evidenced by reductions in ultimate 
load, stiffness, and work-to-failure. Treatment of db/db mice with 
Exenatide led to a slight but not significant increase in ultimate 
load, stiffness, and work-to-failure (Figure 5).
effect of exenatide on BMDD  
in db/db Mice
We aimed to look at modifications of the BMDD to see any possi-
ble alteration in the calcium content of cortical bone (Figure 6A). 
FigUre 4 | Effects of Exenatide on bone nodule formation in vitro under 
normal and high-glucose conditions. Mouse primary osteoblasts were 
isolated from calvaria of 2–3 days old pups and cultured for 28 days in 
six-well plates in osteogenic medium (with addition of ascorbate and 
β-glycerophosphate) in either normal (5.5 mM) or high- (22 mM) glucose 
concentration. Exenatide was added to the cells in normal and high-glucose 
conditions at various concentrations (0, 25, 50, and 100 nM). A control with 
22 mM of mannitol was used as an osmotic control to ensure that changes in 
bone formation is due to glucotoxicity rather than hyperosmolarity. 
Mineralized nodules representing bone formation were scanned and 
observed unstained. Quantification of mineralization was performed using 
Image J. (a) Imaging of bone nodules using contrasting color on photoshop 
to visualize the bone nodules that appear in white. (B) Quantification of the 
area of bone formation by osteoblasts cultured with glucose and Exenatide. 
Mean ± SD of six wells/group. ****P < 0.0001 versus low glucose condition; 
####P < 0.0001, ###P < 0.001 versus no Exenatide. Experiments were 
performed three times in triplicates and graphs are representative of one 
experiment.
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Cawidth, that represents heterogeneity in mineral content, was 
9.5% (P < 0.05) lower in db/db mice compared with lean mice 
(Figure 6B). Four weeks’ treatment with Exenatide increased the 
Cawidth by 17% (P < 0.001) in db/db mice compared with saline-
treated ones (Figure 6B), but had no effect on lean mice. Camean 
and Capeak were not modified by diabetes or Exenatide treatment 
(Figures 6C,D), indicating that the average calcium concentra-
tion was not affected by either.
effect of exenatide on Tissue  
Material Properties at Bone  
Formation sites in db/db Mice
Because there was no alteration in the calcium content of cortical 
bone in db/db mice, tissue material properties were investigated 
at bone formation sites using FTIRM. Mineral/matrix ratio, 
mineral maturity, and carbonate/phosphate ratio were similar in 
the four groups of animals (Figures 7A–C). However, db/db mice 
showed lower collagen maturity (−25%, P < 0.01) than lean mice 
(Figure  7D). Treatment with Exenatide significantly increased 
collagen maturity (+47%, P < 0.001) in db/db mice but had no 
effect on lean mice (Figure 7D).
DiscUssiOn
Among all complications of diabetes mellitus, bone frailty is 
often disregarded by diabetologists despite its high impact on 
life quality. Bone fragility is certainly a consequence of chronic 
hyperglycemia but can also result of direct or indirect effects of 
anti-diabetic drugs. With respect to the conflicting results on 
BMD in T2DM, the underlying mechanisms of bone fragility in 
T2DM seems to be related to the quality rather than the quantity 
of bone tissue, and as such, it is absolutely crucial to ascertain 
how marketed anti-diabetic drugs influence bone quality. In the 
present study, we thought to investigate how Exenatide, a GLP-1 
receptor agonist, marketed for the treatment of type 2 diabetes, 
influences bone quality, remodeling, and strength in a murine 
model of genetically inherited T2DM that reproduces several 
features of human diabetes. Four weeks’ treatment with Exenatide 
was sufficient to improve trabecular bone in T2DM mice by 
increasing bone formation, which could possibly due to the 
observed acute increase in skeletal perfusion. While Exenatide 
did not show significant effect on bone strength and mineral, it 
improved the properties of the matrix by increasing the collagen 
maturity in site of new bone formation. In vitro data suggest that 
Exenatide can promote bone formation by osteoblasts when 
cultured only in high-glucose concentrations.
Leptin has been shown to induce a negative energy balance 
by reducing appetite and increasing energy expenditure (34). 
Although not all obese patients would develop diabetes, most 
patients with T2DM are obese (35). Leptin circulates in serum 
at levels that mirrors body fat. However, obese individuals 
have been found to be resistant to leptin action (36). The long 
form of the leptin receptor is encoded by the db gene and a 
recessive mutation in this gene has been shown to affect the 
intracellular domain of the single membrane-spanning recep-
tor (37). Although leptin appears to bind to its receptor in 
mutant homozygous db/db mice (38), defective intracellular 
signal transduction attenuates leptin function, leading to a 
characteristic phenotype of severe obesity and diabetes, similar 
to what is observed in most human T2DM patients (39, 40), and 
replicated in the present study as demonstrated by low-bone 
mass and severe diabetes. As such, although leptin can also 
have effects on bone independently of diabetes (41, 42), the db/
db mouse represents a good model of T2DM, and reproduces 
the bone phenotype observed in most T2DM. In accordance 
with the literature, chronic administration of Exenatide reduced 
non-fasting plasma glucose in db/db mice (43). It also caused 
a slight reduction in the body mass of these mice, likely due to 
the effect of Exenatide on the central nervous system, where it 
enhances satiety and diminishes food consumption (44).
Previously, improvement in trabecular bone mass have 
been reported in diabetic rodents (cholecystokinin receptor 
A-deficient OLETF rats and Goto-Kakizaki rats) or rodent 
models of ovariectomy-induced osteoporosis in response to 
GLP-1RAs (7, 9, 11, 14). However, although our study confirms 
this finding in the leptin receptor-deficient mice, it also further 
FigUre 5 | Effect of Exenatide on trabecular bone strength in db/db and control mice. Mechanical parameters were recorded in whole left femur using three-point 
bending in 13-week-old db/db and lean mice treated with either Exenatide (10 μg/kg/day) or saline. (a) Examples of load-displacement curves. (B) Ultimate load. 
(c) Ultimate displacement. (D) Stiffness. (e) Work-to-failure. Bars represent mean ± SD of n = 10 mice/group, *P < 0.05, **P < 0.01, ***P < 0.001 versus lean Sal.
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augments our knowledge about the effects of such therapy on 
bone quality that is compromised in animal models of T2DM but 
also in human diabetic individuals. While Exenatide showed an 
anabolic effect in diabetic mice, it did not affect bone mass and 
quality in lean mice, similarly to a previous study (8). Exenatide 
reversed the low-osteoblast activity observed in saline-treated 
mice (augmentations of BFR/BS and MAR, no decrease in 
MS/BS) suggesting that this molecule acts on diabetic bone 
as an anabolic agent. Our results suggest also an uncoupling 
effect, in diabetes, as observed by the lack of effect on osteoclast 
FigUre 6 | Effect of Exenatide on bone mineral density distribution (BMDD) in db/db and control mice. Quantitative backscattered electron imaging was employed 
to determine the BMDD in tibial methylmethacrylate-embedded blocks from 13-week-old db/db and lean mice treated with either Exenatide (10 μg/kg/day) or saline. 
(a) Representative calcium (Ca) map. (B) Characterization of BMDD by Ca width. (c) Characterization of BMDD by Ca mean. (D) Characterization of BMDD by Ca 
peak. Bars represent mean ± SD of n = 10 mice/group, *P < 0.05 versus lean Sal; ###P < 0.001 versus diabetic Sal.
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surface, although it is not a measure of osteoclast activity. This 
finding seems in opposition to our previous published data 
that showed increased osteoclast surfaces and numbers with 
Exenatide in a mouse model of ovariectomy-induced osteopo-
rosis (14). This could be attributed to the animal models used. 
The db/db mouse model is not solely an obese-diabetic model 
and alterations in bone turnover could be attributed to changes 
in leptin signaling and other hormonal levels. Furthermore, 
region-specific differences in bone turnover in db/db mice have 
been shown, with both bone formation and bone resorption 
being either decreased or increased (45). Unfortunately, we 
were not able to analyze osteoclastogenesis and in vitro bone 
resorption by osteoclasts isolated from db/db mice to clarify 
this inconsistency.
Furthermore, at site of bone formation, Exenatide was capable 
of augmenting collagen maturity that is compromised in saline-
treated diabetic mice. The anabolic action of Exenatide can also 
be observed in the higher mineralization heterogeneity observed 
by qBEI that first restore levels similar to non-diabetic animals 
and second reflect the new bone formation that is not yet fully 
mineralized. The latter can also be evaluated from the lower, but 
not significant, Camean values.
FigUre 7 | Effect of Exenatide on tissue material properties assessed at bone formation sites in db/db and control mice. Measurements were performed by 
Fourier-transform infrared microscopy between the fluorescent labels of the trabecular region of tibial sections in 13-week-old db/db and lean mice treated with 
either Exenatide or saline. (a) Mineral-to-matrix ratio. (B) Mineral maturity. (c) Carbonate-to-phosphate ratio. (D) Collagen maturity index. Bars represent mean ± SD 
of n = 10 mice/group, *P < 0.05, **P < 0.01 versus lean Sal; ###P < 0.001 versus diabetic Sal.
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Taken all together, our results support the idea that Exenatide 
ameliorates the bone phenotype, in diabetic mice, through 
an increase in bone formation and that the drug has no effect 
in non-diabetic conditions. It is, however, still not very clear 
whether the increase in bone formation is due to direct effects 
of Exenatide on osteoblasts or to systemic effects. It has been 
shown that the GLP-1R is expressed in marrow mesenchymal 
cells including adipocytes and osteoblasts (14, 46), suggesting 
that the effects of Exenatide on bone formation could be direct 
by binding to the GLP-1R expressed on osteoblasts. Therefore, 
we tested the direct effects of Exenatide on osteoblasts in vitro 
in low- and high-glucose concentrations. Exposure of primary 
osteoblasts to high-glucose concentrations inhibited in  vitro 
bone nodule formation, consistent with previous in vitro studies 
(47, 48). Addition of Exenatide in confluent primary osteoblasts 
cultured in normal glucose conditions did not affect bone nodule 
formation, in accordance with our previous findings showing that 
Exenatide has no effect on bone formation in non-hyperglycemic 
conditions (14). Studies conducted to examine the direct effects 
of GLP-1 agonists on in vitro bone formation have led to incon-
sistent results. Exenatide and Liraglutide were shown to promote 
proliferation and differentiation of a pre-osteoblastic cell line 
(MC3T3-E1) by direct binding to the GLP-1R, suggesting that 
GLP-1RAs could promote osteoblast-mediated bone formation 
(49–51). However, another study has yielded opposite results 
using the same cell line (52). However, the MC3T3-E1 cell line 
does not form trabecular bone nodules, contrary to primary 
osteoblasts used in our study. We cannot exclude, however, that 
Exenatide may exert a direct anabolic effect on bone by increas-
ing proliferation and differentiation of osteoblasts rather than 
affecting their bone forming activity. Interestingly, Exenatide 
directly reduced the deleterious effect of glucose on bone forma-
tion in a dose-dependent manner, while it had no effect under 
normal glucose conditions. This is in agreement with our in vivo 
observation showing that Exenatide exerts no effect in lean mice. 
The mechanisms for the possible protective effects of GLP-1RAs 
against the adverse action of glucose on osteoblasts are still 
unclear. Previous data indicate that culture of osteoblasts in high-
glucose concentrations increases the expression levels of GLP-1R 
mRNA (53), suggesting that GLP-1R may directly link bone 
and glucose metabolism in osteoblasts. Therefore, the observed 
increase in bone formation caused by Exenatide in the presence of 
high-glucose concentrations might be due to upregulated GLP-1R 
expression, which could in turn magnify the effect direct effect of 
GLP-1RAs on osteoblasts. A recent study shows that GLP-1RAs 
facilitate glucose uptake in skeletal muscle cells by activating the 
AMP-activated protein kinase (54). Consequently, GLP-1RAs 
could improve glucose uptake by osteoblasts therefore reducing 
glucotoxicity. This hypothesis needs, however, to be confirmed 
by future overexpression or knockout of GLP-1R studies and by 
testing of insulin signaling and glucose metabolism in osteoblasts 
in response to Exenatide.
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Alternatively, GLP-1RAs may increase bone mass by a systemic 
effect such as an increase in bone blood flow. Patients with T2DM 
demonstrate cardiovascular complications, including endothelial 
dysfunction and impaired vasodilatation (55). Therefore, it would 
be expected that the blood flow to bone is reduced with diabetes. 
The reference method to measure bone blood flow is the intravas-
cular injection of labeled microspheres (56). However, a strong 
correlation was found between the standardized measure of bone 
blood flow and hindlimb perfusion measured using LDI (57), 
indicating that measuring whole hindlimb blood flow is a good 
surrogate method. Similar to what has been observed in humans 
(55), our diabetic mice demonstrated impaired blood flow, indi-
cated by a decrease in hindlimb perfusion. This is in accordance 
with a previous study that showed lower bone and bone marrow 
perfusion in Zucker diabetic rats and suggested that impairment 
of the bone circulation may contribute to the osteopenia observed 
in these rats (58). Furthermore, we have shown that Exenatide 
acutely increased hindlimb perfusion. Similar vasodilator effects 
of Exenatide have been demonstrated in ex vivo studies with 
dilation of the rat femoral artery (59) and thoracic aorta (60). 
However, only one clinical study performed in overweight men 
has shown a beneficial effect of Exenatide on capillary perfusion 
using the laser Doppler technique (61). Consistent with our data, 
the effects of Exenatide were observed rapidly, suggesting direct 
actions of Exenatide on vascular perfusion.
The increased bone formation observed in db/db mice treated 
with Exenatide could be attributed in part to the increased skel-
etal perfusion. Blood supply plays a key role in bone formation 
by transporting oxygen, osteoprogenitor cells, and growth factors 
released from endothelial cells, which control the recruitment, 
proliferation, differentiation, and function of osteoblasts and 
osteoclasts (62). Because vasodilation and angiogenesis both 
contribute to bone blood supply, changes in blood flow could 
indirectly affect bone formation. Since decreased bone formation 
occurs concurrent with reduced hindlimb perfusion in db/db 
mice, this suggests that insufficient perfusion could restrain bone 
formation. This contention is supported by the fact that elderly 
women with osteoporosis have reduced femoral blood flow (63). 
Increased perfusion resulting from Exenatide treatment could 
ameliorate this defect.
Our experiments were performed in male db/db mice that 
exhibit more severe clinical symptoms and we cannot exclude 
potential gender differences regarding the skeletal effects of 
Exenatide in db/db mice. T2DM women treated with Exenatide 
presented more benefit in terms of cardiovascular risk factor and 
body weight (64) that can be attributed to interaction of Exenatide 
with estrogen signaling (65). As there is increased fracture risk 
among T2DM women compared with men, it would be of interest 
to verify our findings in female T2DM models in order to have 
sex-specific treatment guidelines.
In conclusion, administration of Exenatide to leptin receptor-
deficient db/db mice improves bone mass, microarchitecture, and 
quality possibly by (1) reversing the impaired bone formation 
induced by glucose, (2) stimulating bone formation systemically 
via increased hindlimb perfusion, and (3) improving collagen 
content. This study provides additional evidence for the inclusion 
of GLP-1RAs in therapeutic strategies for diabetic patients with 
concurrent bone disease.
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